These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 37119369)
1. Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study. Li YN; Li YY; Wang SX; Ma XY Curr Med Sci; 2023 Jun; 43(3):539-550. PubMed ID: 37119369 [TBL] [Abstract][Full Text] [Related]
2. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053 [TBL] [Abstract][Full Text] [Related]
3. Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method. Song L; Xue J; Zhang J; Li S; Liu D; Zhou T Eur J Pharm Sci; 2021 Mar; 158():105584. PubMed ID: 33039565 [TBL] [Abstract][Full Text] [Related]
4. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866 [TBL] [Abstract][Full Text] [Related]
5. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755 [TBL] [Abstract][Full Text] [Related]
6. Effects of immuno-related gene polymorphisms on a bispecific antibody targeting colorectal cancer cell. Zhang CM; Yu LY; Lv JF; Gong L; Zhou HH; Chen XP; Fan L Per Med; 2018 May; 15(3):167-179. PubMed ID: 29790821 [TBL] [Abstract][Full Text] [Related]
7. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723 [TBL] [Abstract][Full Text] [Related]
8. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Seimetz D; Lindhofer H; Bokemeyer C Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527 [TBL] [Abstract][Full Text] [Related]
9. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. Connor JP; Felder M; Hank J; Harter J; Gan J; Gillies SD; Sondel P J Immunother; 2004; 27(3):211-9. PubMed ID: 15076138 [TBL] [Abstract][Full Text] [Related]
10. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration. Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094 [TBL] [Abstract][Full Text] [Related]
11. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy. Mitra M; Kandalam M; Harilal A; Verma RS; Krishnan UM; Swaminathan S; Krishnakumar S Mol Vis; 2012; 18():290-308. PubMed ID: 22328825 [TBL] [Abstract][Full Text] [Related]
12. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592 [TBL] [Abstract][Full Text] [Related]
13. Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro. Seeber A; Martowicz A; Spizzo G; Buratti T; Obrist P; Fong D; Gastl G; Untergasser G BMC Cancer; 2015 May; 15():372. PubMed ID: 25947366 [TBL] [Abstract][Full Text] [Related]
14. Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab. Seeber A; Braicu I; Untergasser G; Nassir M; Fong D; Botta L; Gastl G; Fiegl H; Zeimet A; Sehouli J; Spizzo G Oncotarget; 2015 Sep; 6(28):25017-23. PubMed ID: 26296970 [TBL] [Abstract][Full Text] [Related]
15. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. Petsch S; Gires O; Rüttinger D; Denzel S; Lippold S; Baeuerle PA; Wolf A MAbs; 2011; 3(1):31-7. PubMed ID: 21107020 [TBL] [Abstract][Full Text] [Related]
16. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy. Frey G; Cugnetti APG; Liu H; Xing C; Wheeler C; Chang HW; Boyle WJ; Short JM MAbs; 2024; 16(1):2322562. PubMed ID: 38445633 [TBL] [Abstract][Full Text] [Related]
17. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Richter CE; Cocco E; Bellone S; Silasi DA; Rüttinger D; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Am J Obstet Gynecol; 2010 Dec; 203(6):582.e1-7. PubMed ID: 20870202 [TBL] [Abstract][Full Text] [Related]
18. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody. Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686 [TBL] [Abstract][Full Text] [Related]
19. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3). Fossati M; Buzzonetti A; Monego G; Catzola V; Scambia G; Fattorossi A; Battaglia A Gynecol Oncol; 2015 Aug; 138(2):343-51. PubMed ID: 26049121 [TBL] [Abstract][Full Text] [Related]
20. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Ruf P; Gires O; Jäger M; Fellinger K; Atz J; Lindhofer H Br J Cancer; 2007 Aug; 97(3):315-21. PubMed ID: 17622246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]